Contraindicated in:
- Hypersensitivity
- Ischemic or vasospastic cardiovascular, cerebrovascular, or peripheral vascular syndromes
- History of significant cardiovascular disease
- Uncontrolled hypertension
- Should not be used within 24 hr of other 5-HT1 agonists or ergot-type compounds (dihydroergotamine)
- Basilar or hemiplegic migraine
- Concurrent MAO-A inhibitor therapy or within 2 wk of discontinuing MAO-A inhibitor therapy
- Phenylketonuria (orally disintegrating tablet [ODT] contains aspartame).
Use Cautiously in:
- Severe renal impairment, especially in patients on dialysis
- Moderate hepatic impairment
- OB: Safety not established in pregnancy
- Lactation: Safety not established in breastfeeding
- Pedi: Safety and effectiveness not established in children <12 yr (oral films) or <6 yr (tablets and ODTs).
Exercise Extreme Caution in:
- Cardiovascular risk factors (hypertension, hypercholesterolemia, cigarette smoking, obesity, diabetes, strong family history, menopausal women or men >40 yr); use only if cardiovascular status has been evaluated and determined to be safe and 1st dose is administered under supervision.
Maxalt, Maxalt-MLT, RizaFilm
Therapeutic Classification: vascular headache suppressants
Pharmacologic Classification: five ht1 agonists
Absorption: Completely absorbed after oral administration, but first-pass metabolism results in 45% bioavailability.
Distribution: Unknown.
Metabolism/Excretion: Primarily metabolized by monoamine oxidase-A (MAO-A); minor conversion to an active compound; 14% excreted unchanged in urine.
Half-life: 2–3 hr.
40 kg): Tablet or ODT: 10 mg single dose (use 5-mg dose in patients receiving propranolol).